Tempest Therapeutics (3OS0) Stock Statistics & Valuation Metrics
Total Valuation
Tempest Therapeutics has a market cap or net worth of EUR 8.87M. The enterprise value is EUR 23.68M.
- Market Cap
- EUR 8.87M
- Enterprise Value
- EUR 23.68M
Share Statistics
Tempest Therapeutics has 19,995,358 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,995,358
- Owned by Insiders
- 1.16%
- Owned by Institutions
- 5.45%
Financial Efficiency
Tempest Therapeutics’s return on equity (ROE) is -3.94 and return on invested capital (ROIC) is -179.45%.
- Return on Equity (ROE)
- -3.94
- Return on Assets (ROA)
- -1.55
- Return on Invested Capital (ROIC)
- -179.45%
- Return on Capital Employed (ROCE)
- -1.95
- Revenue Per Employee
- 0
- Profits Per Employee
- -6.57M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tempest Therapeutics is -0.11. Tempest Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.11
- PS Ratio
- 0.00
- PB Ratio
- -6.92
- Price to FCF
- -0.48
- Price to Operating Cash Flow
- -0.36
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Tempest Therapeutics had revenue of 0 and earned -26.26M in profits. Earnings per share was -6.33.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -26.57M
- Pretax Income
- -26.26M
- Net Income
- -26.26M
- EBITDA
- -25.79M
- Earnings Per Share (EPS)
- -6.33
Cash Flow
In the last 12 months, operating cash flow was -20.73M and capital expenditures 0, giving a free cash flow of -20.73M billion.
- Operating Cash Flow
- -20.73M
- Free Cash Flow
- -20.73M
- Free Cash Flow per Share
- -1.36
Dividends & Yields
Tempest Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -209.23%
- Earnings Yield
- -536.52%
Stock Price Statistics
- Beta
- 1.47
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 5.94
- 200-Day Moving Average
- 5.94
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Tempest Therapeutics upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Tempest Therapeutics as a current ratio of 2.50, with Debt / Equity ratio of 122.09%
- Current Ratio
- 2.50
- Quick Ratio
- 2.50
- Debt to Market Cap
- 0.58
- Net Debt to EBITDA
- -0.02
- Interest Coverage Ratio
- -128.38
Taxes
In the past 12 months, Tempest Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Tempest Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.81.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.41
- EV to Free Cash Flow
- -0.81
- EV to Operating Cash Flow
- -0.81
Balance Sheet
Tempest Therapeutics has EUR 779.00K in cash and marketable securities with EUR 7.56M in debt, giving a net cash position of -EUR 6.78M billion.
- Cash & Marketable Securities
- EUR 779.00K
- Total Debt
- EUR 7.56M
- Net Cash
- -EUR 6.78M
- Net Cash Per Share
- -EUR 0.34
- Tangible Book Value Per Share
- -EUR 0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tempest Therapeutics is EUR 6.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 6.29
- Price Target Upside
- 5.97% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 71.55%
